Wall Street brokerages expect Endocyte, Inc. (NASDAQ:ECYT) to announce ($0.16) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Endocyte’s earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.15). Endocyte posted earnings of ($0.26) per share during the same quarter last year, which indicates a positive year over year growth rate of 38.5%. The business is scheduled to announce its next quarterly earnings results on Friday, March 9th.
On average, analysts expect that Endocyte will report full-year earnings of ($1.24) per share for the current fiscal year, with EPS estimates ranging from ($1.25) to ($1.23). For the next year, analysts anticipate that the firm will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.02) to ($0.79). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Endocyte.
Endocyte (NASDAQ:ECYT) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.20). The firm had revenue of $0.03 million for the quarter. Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.21) EPS.
In related news, insider Philip S. Low acquired 5,600 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was bought at an average cost of $4.84 per share, for a total transaction of $27,104.00. Following the purchase, the insider now owns 283,005 shares in the company, valued at approximately $1,369,744.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Philip S. Low sold 50,511 shares of the business’s stock in a transaction that occurred on Thursday, December 28th. The stock was sold at an average price of $4.41, for a total value of $222,753.51. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 124,253 shares of company stock valued at $562,591. 14.86% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ECYT. Dimensional Fund Advisors LP lifted its holdings in Endocyte by 34.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 25,003 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Endocyte by 1,064.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock worth $646,000 after purchasing an additional 393,975 shares in the last quarter. Finally, FMR LLC lifted its holdings in Endocyte by 0.9% in the 2nd quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock worth $5,310,000 after purchasing an additional 31,168 shares in the last quarter. 17.45% of the stock is currently owned by institutional investors.
Endocyte (NASDAQ ECYT) traded up $0.03 during trading on Tuesday, hitting $3.98. The company’s stock had a trading volume of 306,500 shares, compared to its average volume of 399,593. The company has a market cap of $169.45, a P/E ratio of -2.95 and a beta of 2.20. Endocyte has a 1-year low of $1.17 and a 1-year high of $6.55.
TRADEMARK VIOLATION NOTICE: “Analysts Expect Endocyte, Inc. (ECYT) to Post -$0.16 Earnings Per Share” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/23/analysts-expect-endocyte-inc-ecyt-to-post-0-16-earnings-per-share.html.
Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.